Close
Photo courtesy of NIAID
View image caption

In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months. However, PrEP use fell among participants in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored, evidence-based adherence support strategies may be needed to durably engage young African women in consistent PrEP use. 

Connie Celum, professor of Global Health, is quoted in this story.

Read the entire article at National Institute of Allergy and Infectious Diseases and a related story in the Imperial Valley News.